Ionis teams with Metagenomi and dives into gene editing
Bio Pharma Dive
NOVEMBER 14, 2022
The RNA drug developer is paying the richly-funded startup $80 million in a wide-ranging alliance that marks its first foray into DNA editing medicines.
DNA Medicine RNA 
Pfizer drops the blue pill, kicks off 2021 with new DNA logo
pharmaphorum
JANUARY 6, 2021
Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. Encoded within a successful emblem is a company’s DNA – its history, its future.
DNA 
116
116 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT+: After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing
STAT News
NOVEMBER 14, 2022
Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA. On Monday, the company announced a partnership with Metagenomi to kickstart these efforts.
Gene Editing 98
98 
Moderna’s founder launches Laronde, promising new ‘Endless RNA’ drug class
pharmaphorum
MAY 11, 2021
Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.
RNA 98
98 
General Design Methods for mRNA Drugs
Pharma Mirror
APRIL 21, 2024
With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.
In-Vitro 130
130 
A new hub for developing medicines of the future at the University of Gothenburg
Scienmag
MARCH 1, 2021
Credit: Johan Wingborg In recent years, techniques have been developed to treat diseases with what are known as oligonucleotide drugs, based on short DNA or RNA molecules.
Medicine 84
84 
Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
Genomic medicine is a rapidly growing space in which researchers use the information in a person’s genes to identify and administer medical treatment.”. The evolving field of genomic medicine. There are two components to genomic medicine, known as the payload and the vector.
Genomics 105
105 
Novel, sensitive, and robust single-cell RNA sequencing technique outperforms competition
Scienmag
JUNE 27, 2022
The advent of single-cell RNA sequencing (scRNA-seq) has revolutionized the fields of medicine and biology by providing the ability to study the inner workings of thousands of cells at one go.
RNA 56
56 
Leading innovators in ssRNA virus peptides for the pharmaceutical industry
Pharmaceutical Technology
MAY 8, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These viruses carry the genetic information to synthesise an RNA-dependent RNA polymerase.
RNA 240
240 
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.
Vaccine 293
293 
Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal
The Pharma Data
JANUARY 5, 2021
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. The first identifies the 3D RNA motifs.
RNA 52
52 
Scientists implicate non-cardiac genes in congenital heart disease
Scienmag
APRIL 27, 2022
CHAPEL HILL, NC – Inside embryonic cells, specific proteins control the rate at which genetic information is transcribed from DNA to messenger RNA – a crucial regulatory step before proteins are created. Then, organs develop and hopefully function properly.
Scientist 83
83 
Key Trends in the Life Sciences to Look Forward to in 2022
XTalks
DECEMBER 22, 2021
The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. RNA technology is not new nor has its potential been surprising. RNA in the Making. So why did this perceived RNA ‘revolution’ take so long?
Life Science 98
98 
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
The Pharma Data
FEBRUARY 22, 2022
State-of-the-art facility will headquarter research efforts in Boston and New York to accelerate the development of RNA and DNA-based medicines. Adams, vice president of genetic medicine at Lilly and co-director of the Institute. ” The Institute will be headquartered in 334,000 sq.
Genetics 52
52 
RNA Therapeutics: A Novel Approach to Treating Diseases
Roots Analysis
OCTOBER 22, 2023
RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.
RNA 40
40 
The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans
Worldwide Clinical Trials
AUGUST 14, 2024
They play a crucial role in tailoring hematology oncology therapeutic strategies to individual patients and have transformed personalized medicine in oncology. Molecular Biomarkers : Encompass various molecules, such as RNA and metabolites, to reflect the physiological state of the cells and their disease pathways.
Genetics 195
195 
Moderna partners with Life Edit for mRNA gene editing therapies
Pharmaceutical Technology
FEBRUARY 23, 2023
The gene editing platform of Life Edit provides an extensive and diverse library of base editors and RNA-guided nucleases (RGNs), which are smaller in size than conventional nucleases. The company’s nuclease collection includes several Protospacer Adjacent Motifs (PAMs), short sequences that help determine the genome’s DNA segments.
Gene Editing 147
147 
Verve starts trials of cholesterol drug in test of base editing technique
pharmaphorum
JULY 13, 2022
Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene. However, they can lead to unwanted effects such as insertions, deletions, or other DNA rearrangements at the site of the break which raises the risk of side effects. Today: we are announcing.
Gene Editing 98
98 
A new dawn of the genomic age: five areas set to be transformed in 2023
pharmaphorum
JANUARY 26, 2023
In March, the collaborative T2T consortium published the first complete telomere-to-telomere sequence of the human genome, filling in the last 8% of the 3 billion base pairs that make up our DNA. For example, the commonly prescribed pain relief drug codeine is not effective in around 8% of the UK population.
Genomics 129
129 
AI in pharma: Can it be used in DTC?
World of DTC Marketing
FEBRUARY 7, 2021
Measuring RNA, DNA quickly. Precision medicine or next-generation sequencing helps in the faster discovery of drugs and tailored medication for individual patients. . Drug Discovery and Manufacturing: It helps in the initial screening of drug compounds to the predicted success rate based on biological factors.
Doctor 164
164 
Verge Genomics takes AI-sourced drug for ALS into clinic
pharmaphorum
OCTOBER 31, 2022
VRG50635 was discovered using Verge’s AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using data on DNA, RNA and protein profiles to identify new targets and drug that can interact with them.
Genome 136
136 
Shining a light on the role of the genome’s ‘dark matter’ in cancer development
Scienmag
NOVEMBER 16, 2020
doi:10.1186/s13073-020-00788-5… SINGAPORE, 3 Nov 2020 – Long RNA molecules carrying DNA codes that […]. Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Genome Med 12, 89 (2020).
In-Vivo 53
53 
Scientists identify new types of a blood cancer and potential targeted treatments
The Pharma Data
NOVEMBER 17, 2021
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.
Scientist 52
52 
Discovery of MicroRNA Genetic Regulation Leads American Scientists to Win 2024 Nobel Prize
XTalks
OCTOBER 8, 2024
The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their groundbreaking discovery of microRNA (or miRNA) and its role in post-transcriptional gene regulation. A gene contains instructions within our DNA.
Regulation 52
52 
Top 10 Fastest Growing Biotech Companies in 2023
XTalks
DECEMBER 13, 2023
Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. In the third quarter of 2023, the company’s revenue surged to $63.7
Genetics 111
111 
Casting aside CRISPR scissors and making a point with base editors
pharmaphorum
FEBRUARY 3, 2021
However, caveats surrounding the stochastic off-target outcomes of cleaving both strands of the DNA helix to elicit a gene modification remain a source of concern. Traditional CRISPR-Cas9 technology relies on generating a DSB in the DNA to facilitate a genetic modification. Base editing to get cell therapies on point.
Gene Editing 98
98 
Next Generation Sequencing (NGS) Library Preparation Kits Market: Current Scenario and Future Potential
Roots Analysis
FEBRUARY 21, 2022
Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. As per our analysis, majority of the kits use purified RNA / DNA as the input sample. Diverse Landscape of NGS Library Preparation Kits.
Marketing 52
52 
Protein can release trapped histones in the cell
Scienmag
APRIL 14, 2021
In the cell nucleus histones play a crucial role packaging DNA into chromatin. Histones are however very sticky to both DNA and RNA, so to ensure they are transported to the cell nucleus after synthesis and bind to the right portion of DNA to organize the chromatin, they are guarded by complexes of histone chaperones. […].
Protein 40
40 
Moderna and BioNTech – who are they?
pharmaphorum
DECEMBER 21, 2020
Compared with many of the established names in pharma these companies are young upstarts but they have managed to achieve what other big names in the industry have failed to do and harness the power of mRNA to make medicine. This will revolutionise medicine over the next 10-15 years in areas we do not even imagine.”.
Vaccine 111
111 
AI-designed protein awakens silenced genes, one by one
The Pharma Data
MARCH 7, 2022
Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports. The AI-designed protein was developed at the UW Medicine Institute for Protein Design (IPD) under the leadership of David Baker, also a professor of biochemistry and head of the IPD.
Protein 52
52 
Looking at Women’s Leadership in Life Science Industries on International Women’s Day
XTalks
MARCH 8, 2022
From leading COVID-19 vaccine developments to being at the helm of the latest gene therapies and inventing ground-breaking DNA technologies like CRISPR, women have been at the forefront of some of the most leading-edge scientific discoveries in recent years, both as innovators and leaders.
Life Science 105
105 
Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer
Delveinsight
FEBRUARY 25, 2021
Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. The gene-editing technologies, which have reached the clinic, CRISPR, zinc finger nucleases, and TALENs, make their edits by nicking DNA at the target site.
DNA 52
52 
CRISPR Cas-9 System Doubles Life Expectancy in Mice with Aggressive Cancers
The Pharma Data
NOVEMBER 22, 2020
Back in September, Vertex Pharmaceuticals and CRISPR Therapeutics – the company behind the CRISPR Cas-9 platform – announced that the European Medicines Agency (EMA) had granted Priority Medicines (PRIME) designation to CTX001, an investigational ex vivo CRISPR Cas-9 gene-edited therapy for the treatment of severe sickle cell disease.
Gene Editing 52
52 
The Utility of Liquid Biopsy in Oncology Clinical Trials
XTalks
NOVEMBER 7, 2022
Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). FoundationOne ® Liquid CDx (Foundation Medicine; end-to-end commercial provider).
Bayer bolsters R&D platform with $2bn Vividion takeover
pharmaphorum
AUGUST 5, 2021
Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against targets once considered “undruggable.” ” Bayer is paying $1.5
DNA 52
52 
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
The Pharma Data
JUNE 7, 2023
Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. This delivery technology protects the messenger RNA (mRNA) payload after administration allowing it to be safely and effectively delivered into cells.
Gene Therapy 40
40 
Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare
Roots Analysis
JANUARY 28, 2024
Pharmaceutical Research: Big data analytics can be applied in various areas of pharmaceutical research, including drug discovery and development, precision medicine , clinical trial optimization, pharmacovigilance and drug safety, supply chain optimization, and real-time monitoring and surveillance.
Big Data 40
40 
Winship Cancer Institute of Emory University Joins Caris’ Precision Oncology Alliance
The Pharma Data
OCTOBER 19, 2020
Caris’ collaborative network focused on expanding the application of precision medicine in oncology supports Winship’s enterprising approach to research leading to transformative discoveries in cancer care and treatment. IRVING, Texas and ATLANTA , Oct.
Life Science 52
52 
Molecular Diagnostic Tests: The Unsung Hero of Precise Clinical Decision Making
Roots Analysis
AUGUST 12, 2024
Molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicine. Molecular diagnostic tests refer to tests intended to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease.
Genetics 40
40 
Recurring brain tumor growth is halted with new drug
The Pharma Data
MAY 9, 2022
But now Northwestern Medicine scientists, in an international collaboration with scientists at the University of California, San Francisco and the University of Hong Kong, have identified a drug that inhibits growth of the most aggressive meningiomas and how to most accurately identify which meningiomas will respond to the drug. .
Drugs 52
52 
Uptick in Clinical Trial Complexity: How Can You Achieve Your Clinical Trial Objectives Faster?
XTalks
JANUARY 8, 2024
Whether it’s for a treatment for a chronic ambulatory condition, precision medicine or cell and gene therapy, there is a massive uptick in clinical trial complexity. The proper handling of certain time-sensitive samples is vital, such as those for flow cytometry, peripheral blood mononuclear cell (PBMC) processing, and RNA and DNA extraction.
Clinical Trials 105
105 
What the Glycome Can Tell Us About Persistent HIV Infection
XTalks
AUGUST 12, 2020
Studies have identified the presence of two types of HIV-infected CD4+ T cells: ‘Transcriptionally inactive’ cells that do not typically produce viral RNA or viral proteins. Transcriptionally active’ cells in which HIV RNA is actively transcribed to make copies of the virus (despite long-term ART).
RNA 52
52 The Booming Potential of mRNA Technology
Roots Analysis
AUGUST 23, 2024
In recent years, mRNA technology has rocked the world of medicine, making it possible to prevent and treat a vast array of diseases and disorders. Unveiling The Potential of mRNA Technology mRNA is a single-stranded molecule that relays the genetic instructions needed to make proteins from DNA in the cell nucleus to ribosomes.
Protein 40
40 
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
The Pharma Data
JANUARY 21, 2021
CABENUVA, a co-packaged kit with two injectable medicines, offers people living with HIV a new approach for maintaining viral suppression. In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 50 c/mL, meeting noninferiority criteria.
FDA Approval 52
52 
Let's personalize your content